Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating patients who have acute myelogenous leukemia that did not respond to standard treatment given in clinical trial PDL 195-301.

Timeline

Start

2001-02

Primary completion

—

Completion

—

Drugs

Indications